WeCare Probiotics Reimagines Customer Value with Clinical Evidence-Based Science at the 2025 China Gut Conference

Ningbo, China – June 8, 2025 – WeCare Probiotics actively participated in the grand 2025 China Gut Conference, held from June 6th to 8th at the Ningbo International Convention Center. This event, recognized as a global-scale academic and industrial gathering focused on gut health, brought together representatives from the academic, clinical, and industrial sectors worldwide. WeCare Probiotics joined this esteemed group to focus on cutting-edge gut research and discuss innovative developments in the field of gut health.

During the main forum of the conference, Dr. Devin Zhu of the WeCare Probiotics Research Institute delivered a compelling presentation titled "Clinical Evidence-Based Research and Large-Scale Intelligent Manufacturing of Probiotics." Dr. Zhu provided in-depth insights into the technical barriers and industrialization pathways for developing clinical probiotic strains. He also offered a global perspective, discussing future growth opportunities for the probiotic industry in the era of precision health.

Clinical evidence-based research, with its authority, scientific rigor, and reliability, has become a crucial competitive advantage for companies in the probiotic market. Both domestic and international market trends clearly indicate that clinical research is now the primary battleground for the development of the probiotic industry.

WeCare's Perspective

WeCare Probiotics has comprehensively invested in clinical research for its WecLac® series of core strains, including Weizmannia (Bacillus) coagulans BC99™, Bifidobacterium animalis subsp. lactis BLa80, Lacticaseibacillus rhamnosus LRa05, and next-generation probiotics like Akkermansia muciniphila Akk11. The company has initiated over 100 randomized controlled trials (RCTs) globally, with more than 78 clinical trials already completed. These studies span across six major health areas, including digestive health, immune regulation, and metabolic management, covering over 20 research directions. This extensive research aims to provide global consumers with more scientifically sound and effective health support.

For many years, WeCare Probiotics has consistently remained at the forefront of probiotic strain research. The company focuses on the field of probiotic strains, using rigorous clinical evidence-based scientific methods to validate strain functions. Its large-scale intelligent manufacturing capabilities provide a strong impetus for product innovation in the industry. Looking ahead, WeCare Probiotics is enthusiastic about collaborating with numerous authoritative experts and researchers to delve deeper into cutting-edge topics in probiotic strains and gut health.